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Abstract: In the text that follows, we review the main clinical features, genetic character-
istics, and treatment options for Parkinson’s disease (PD), considering the age at onset. The 
clinical variability between patients with PD points at the existence of subtypes of the disease. 
Identification of subtypes is important, since a focus on homogenous group may lead to tailored 
treatment strategies. One of the factors that determine variability of clinical features of PD is 
age of onset. Young-onset Parkinson’s disease (YOPD) is defined as parkinsonism starting 
between the ages of 21 and 40. YOPD has a slower disease progression and a greater incidence 
and earlier appearance of levodopa-induced motor complications; namely, motor fluctuations 
and dyskinesias. Moreover, YOPD patients face a lifetime of a progressive disease with gradual 
worsening of quality of life and their expectations are different from those of their older coun-
terparts. Knowing this, treatment plans and management of symptoms must be paid careful 
attention to in order to maintain an acceptable quality of life in YOPD patients.
Keywords: therapy, clinical features, dopamine agonist, levodopa, dyskinesia
Introduction
Young-onset Parkinson’s disease (YOPD) is a subtype of Parkinson’s disease (PD), 
occurring at a younger age, with specific symptoms, genetic correlation, and treatment 
strategies. YOPD is defined as the diagnosis of PD between the ages of 21 and 40.1 A 
positive PD diagnosis under the age of 21 is referred to as “juvenile Parkinson’s” (JP). 
Between 3% and 6% of all PD cases are reported to be YOPD.1–3 Although most clinical 
features of JP and YOPD are the same, increased occurrence of dystonia and PD are 
found in families of patients with JP.4 The overall age and gender adjusted incidence 
of PD is 13.4 per 100,000, whereas the incidences for people between the ages of 
30 and 39, 40 and 49, and 50 and 59 are 0.5, 2.5, and 9.8 per 100,000, respectively.5 
Approximately 20% of YOPD patients have at least one first- or second-degree rela-
tive with PD either in the same or antecedent generation.6 The aim of this review is to 
give an overview of specific clinical manifestations, genetic background, and potential 
environmental factors of YOPD with strong focus on current treatment options and 
strategies available for YOPD.
Clinical manifestations
Although the diagnosis of YOPD is based on clinical symptoms and family history 
of Parkinson’s disease or any other movement disorders, there must be exclusion 
of secondary causes of parkinsonian symptoms. Some of these secondary causes 
include Wilson’s disease, dopa-responsive dystonia, drug-induced parkinsonism, 
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spinocerebellar ataxia, iron accumulation disorders, and 
structural abnormalities. To exclude these possible second-
ary causes, such as drug-induced parkinsonism, a detailed 
history of all neuroleptic and antiemetic drug use should be 
recorded. Measurement of serum and urinary copper, and 
screening for Kayser–Fleischer rings should be performed 
to exclude Wilson’s disease.
Motor symptoms
The classical clinical appearance of PD consists of a resting 
tremor (3–6 Hz, usually unilateral on presentation), cog-
wheel rigidity, bradykinesia, and sometimes compromised 
postural reflexes and gait instability.7,8 Another sign, which 
is 100% sensitive but not completely specific for PD, may be 
a positive response to levodopa.7 The symptoms that appear 
in YOPD are similar to the classical symptoms of late-onset 
PD (LOPD), but some clinical features seem to be more 
prominent in YOPD.
In one study comparing clinical symptoms of YOPD 
versus LOPD it was concluded that YOPD patients more com-
monly present with increased muscle stiffness (43%), while 
LOPD patients more often present with increased difficulty 
walking later on in the illness (33%).9 Postural instability is 
more commonly seen in LOPD than in YOPD.1
It was shown that “wearing-off,” “on–off ” dystonia, and 
levodopa dyskinesia10 as well as dyskinesia in general11 were 
much more prominent in YOPD patients (59% versus 37%).12 
Although, as previously mentioned, this very well could be 
a side effect of therapy.1,11,13,14 More specifically, it has been 
demonstrated that the most common type of dyskinesia is 
peak-dose dyskinesia, which includes stereotypic, choreic, 
or ballistic movements involving the head, trunk, limbs, and 
occasionally respiratory muscles.15–17 Another study con-
firming these findings showed that about one-third of YOPD 
patients had off-period dystonia, while LOPD patients were 
not observed to have dystonia during the study.9 The differ-
ences observed in the prevalence of tremor and bradykinesia 
between YOPD and LOPD were not statistically significant.10 
YOPD patients were also shown to have increased motor 
fluctuations (69%) in comparison to LOPD patients (46%).12 
In JP dystonia (60% in JP versus 14% for YOPD) and aki-
netic rigidity (69% in JP versus 20% for YOPD) are much 
more common.18
Non-motor symptoms
It has been demonstrated that after median disease duration 
of 18 years, the prevalence of cognitive impairments is only 
19%, of which 13% is under the age of 60.19 YOPD patients 
have a decreased incidence of cognitive degeneration when 
compared with LOPD.1,18–20 It has been postulated that there 
may be a difference in the types of Parkinson’s between 
YOPD and LOPD with motor deterioration predominating the 
symptoms of YOPD and mental deterioration predominating 
the symptoms of LOPD.21
YOPD patients have been shown to have many psycho-
logical symptoms such as psychosis, confusion, and even 
hallucinations; these symptoms were present in only 13% 
of patients who had disease duration less than 10 years, 
and positively correlated with the duration of disease.18 
Depression was also correlated with YOPD, this was postu-
lated to possibly be a consequence of a longer duration of 
disease and decreased quality of life due to a high prevalence 
of motor symptoms.22 It was found that the mortality rate 
associated with YOPD is twice that of the normal popula-
tion, but when compared with other PD patients it does not 
statistically vary.2,23,24
Paresthesias were also found to be in 20.5% of YOPD 
patients compared with 2% of the LOPD patients.11 Other 
non-motor symptoms, which were found to be more common 
in YOPD patients in comparison with LOPD patients, were 
restless legs and sweating.12 The presence of symptoms in 
YOPD and LOPD is shown in Table 1.
Diagnosis
The diagnosis of YOPD is still widely based on the judg-
ment of clinical symptoms. The recently US Food and 
Drug Administration (FDA)-approved DaTSCAN is being 
questioned for its accuracy and overall contribution to the 
diagnosis of PD. It has been shown that the overall accuracy 
of clinical diagnosis is 84% in early PD and 98% at later 
stages of PD. The diagnosis of PD clinically is mathemati-
cally just as accurate as the diagnostic accuracy of DaTSCAN 
imaging.25 It must be kept in mind that the purpose of a 
Table 1 Occurrence of symptoms in young- and late-onset 
Parkinson’s disease
Young-onset Parkinson’s  
disease
Late-onset Parkinson’s 
disease
• Motor fluctuations • Postural instability
• “Off-time” dystonia • Difficulty walking
• Muscle stiffness • Cognitive degeneration
• Dyskinesia
• Psychosis, confusion, hallucinations
• Depression
• Paresthesias
• Restless legs
• Sweating
 
D
eg
en
er
at
ive
 N
eu
ro
lo
gi
ca
l a
nd
 N
eu
ro
m
us
cu
la
r D
ise
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
16
1.
53
.2
22
.5
2 
on
 3
0-
M
ar
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
Degenerative Neurological and Neuromuscular Disease 2013:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
55
Management of young-onset Parkinson’s disease
DaTSCAN is to aid in the diagnosis of PD and not to be a 
replacement of the clinical diagnosis.
It has also been shown that transcranial ultrasound can 
show hyperechogenicity in the substantia nigra of a PD 
patient.26–28 It has been postulated that this is due to the 
increased concentration of iron in some patients with PD.26–29 
Furthermore, lower serum ceruloplasmin levels have been 
correlated with a younger onset of PD.26
Genetic background and potential 
environmental factors in YOPD
The genetic contribution to the etiology of YOPD is probably 
greater than in PD with later onset.30 Out of several genes, 
assumed to be associated with YOPD, five stand out and are 
mentioned more frequently in current literature than others 
(Table 2).31 Mutations in the PARK2 gene are the most com-
mon cause of autosomal recessive YOPD31–34 with an onset 
before age 40.35 PARK2 is an E3-type ubiquitin protein 
ligase involved in the proteosomal degradation of target 
proteins, including α-synuclein.36 The accumulation of this 
protein results in neuronal death in substantia nigra and locus 
ceruleus.36 The second most common cause of autosomal 
recessive YOPD is PINK1 gene mutation. The discovery of 
PINK1 involvement in PD was the first evidence that a kinase 
signaling pathway could be important in the pathogenesis of 
dopaminergic nigral cell death.37 Moreover, it provided a link 
between mitochondrial dysfunction and neurodegeneration 
seen in PD.38,39 Another gene thought to be associated with 
YOPD is PARK7, involved in protection from oxidative stress 
and chaperoning proteins such as α-synuclein.36 PD associ-
ated with LRRK2 mutations presents an onset distribution 
very similar to that seen in idiopathic PD, as well as clear 
age-dependent penetrance.40–42 In 2009, Tong et al demon-
strated that LRRK2 mutation affects activity-dependent 
dopamine (DA) neurotransmission and catecholamine 
release.43 Lastly, mutations in SNCA, although rare, cause 
PD to occur at a younger age than that seen for idiopathic 
PD.44 Given the correlation described recently between 
LRRK2 and SNCA45,46 and the impact of α-synuclein over-
expression on synaptic vesicle recycling,47 the regulation 
of neurotransmitter release might arise as one of the main 
biological pathways compromised during neuropathology 
onset.48 Additionally, a study conducted by Nichols et al 
suggests that patients carrying a glucocerebrosidase (GBA) 
variant exhibited PD symptoms 6.04 years earlier than those 
without a GBA variant.49 It is also important to note that the 
abovementioned LRRK2, SCNA, and GBA gene mutations 
increase the risk of sporadic PD, whereas many others are 
linked to familial forms of PD.
Apart from genes, environmental factors may also play a 
role in YOPD etiology. A study from Sao Paulo by Aguiar at al 
observed higher exposure to well-water drinking in the YOPD 
patient group. Most of the patients were exposed during first or 
second decades of life, for an average period of 14.3 years.34 
Other potential environmental risk factors included pesticides, 
herbicides, and organic solvents. An inverse association 
between smoking and PD risk was not observed, suggest-
ing a putative protective effect smoking might have on PD 
 development. However, the authors argued that in the case of 
YOPD, the protective effects of smoking were not enough to 
overcome all other factors leading to neurodegeneration.
Current treatment options  
and strategies available for YOPD
Pharmacological treatment
Which drugs to use when initiating pharmacotherapy in 
YOPD is a complex treatment decision that depends on 
factors such as disease severity, functional disability, and 
psychosocial handicap, as well as individual aspects of 
comorbidity and age. To date, the most effective treatment for 
PD has been shown to be levodopa. It is effective in treating 
symptoms such as bradykinesia and rigidity. The effects of 
levodopa on postural stability, speech, and gait disturbance 
is less pronounced.
Initially, YOPD patients have a good response to levodopa 
therapy, but as treatment progresses, motor symptoms resis-
tant to levodopa develop.6,13,21 It seems that YOPD patients 
Table 2 Genes found to be significant in young-onset Parkinson’s 
disease etiology and their mode of inheritance
Mode of inheritance
Autosomal recessive Gene product Function
PARK2 
(OMiM*602544)
Parkin Plays a role in the cell  
machinery that degrades  
unneeded proteins
PiNK1 
(OMiM*608309)
PTeN induced  
putative kinase 1
Helps protect mitochondria 
from malfunctioning during 
period of cellular stress
PARK 7 
(OMiM*602533)
DJ-1 protein Helps protect cells from 
oxidative stress
Autosomal dominant
LRRK2 
(OMiM*609007)
Dardarin Plays a role in activities that 
require interactions with  
other proteins, such as  
transmitting signals
SNCA 
(OMiM*163890)
α-synuclein Plays a role in maintaining a 
supply of synaptic vesicles 
in presynaptic terminals
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have a slower progression of disease but higher treatment 
complications with levodopa.1,11,13,14 In YOPD, treatment with 
levodopa is associated with early and prominent occurrence 
of motor complication, namely dyskinesia. In one study, it 
was observed that within the first week of treatment with 
levodopa, 25% of patients developed a complication; after 
5 years of levodopa treatment, 91% of patients developed 
dyskinesias, and 92% developed motor fluctuations; and after 
12 years, all patients had those side effects.21 A similar trend 
was demonstrated by a study done in 1987, where 100% 
of patients developed dyskinesias by the sixth year after 
therapy.6 Therefore, the treatment with levodopa should be 
postponed in this group of patients, although every PD patient 
progresses to the point where levodopa is necessary.50
Alternative treatment options to start therapy in YOPD 
are dopamine agonists, inhibitors of monoamine oxidase B 
(selegiline hydrochloride, or rasagiline mesilate), amantadine 
hydrochloride, or where tremor is a particular problem, anti-
cholinergics – although use of the latter might be restricted 
by cognitive side-effects.51,52 All of these drugs can be used 
alone or in combination with levodopa to successfully treat 
PD. The decisions as to when to start drug treatment and 
which drugs to use in patients with YOPD depend on sev-
eral factors, including disease severity, functional disability, 
comorbidity, personal expectations, employment status, and 
psychosocial handicap.50
Evidence suggests that the use of dopamine agonists 
rather than levodopa is associated with a decreased risk of 
developing motor complications.53–57 Long-term follow-up 
trials have confirmed that there are fewer dyskinesias and 
motor fluctuations in patients treated with dopamine agonists, 
but a decrease in moderate to severe dyskinesias was not 
noted to be very significant.58–60 This delay of dyskinesias 
and motor complications may be most appreciated in patients 
with YOPD.61 There is also some evidence that dopamine 
agonists may have a neuroprotective effect.62 This has been 
supported by functional imaging studies which demonstrate a 
decreased rate of decline of presynaptic dopaminergic func-
tions.63,64 However, this conclusion comes from correlating 
the changes in imaging techniques rather than the clinical 
picture. Nonetheless, this information has led us to believe 
that starting therapy with dopamine agonists rather than 
levodopa could be beneficial. However, one must keep in 
mind that dopamine agonists also have many side effects. In 
PD patients treated with dopamine agonists, impulse control 
disorders including gambling, shopping, binge eating, and 
hypersexuality are observed. Other observed side effects 
of dopamine agonists are increased daytime sleepiness, leg 
edemas, and early hallucinations.65–67 However, the method 
of treatment which has been most supported for YOPD is 
initiation of treatment with dopamine agonists, increasing 
the dose until a balanced level of effectiveness and the level 
of maximum tolerance is reached. Levodopa is then added as 
adjuvant therapy as needed.68,69 This method of therapy seems 
most suitable in YOPD for avoiding early motor symptoms 
due to levodopa treatment.
Monoamine oxidase (MAO)-B inhibitors are effective 
in monotherapy and as an adjunct to levodopa therapy, with 
beneficial effects on quality of life parameters in early and 
late stages of PD. Studies have shown that MAO-B inhibitors 
reduce the incidence of motor fluctuations, decrease the need 
for levodopa, and reducing overall disability, with negligible 
side effects. The MAO-B inhibitors, used as monotherapy, 
delay the need for the introduction of levodopa by about 
9 months. These agents appear to be less efficacious than 
dopamine agonists but are better tolerated.70
Amantadine could be used as a monotherapy or in 
combination with levodopa. There is some evidence that 
amantadin is useful in controlling dyskinesias, but evidence 
of its effectiveness in treating motor complications has not 
been convincing.71,72 Amantadine has been shown to reduce 
dyskinesia by 45% in patients with PD when it was compared 
with a placebo, but the positive effects were only sustained 
for 8 months, and when the patient experienced withdrawal 
from amantadine, there was an up to 20% increase in dys-
kinesias.73 Therefore, amantadine is usually used as add-on 
therapy when dyskinesias develop.
Anticholinergics are nowadays rarely used due to side 
effects such as cognitive disturbances. Sometimes one may 
consider using anticholinergics for treatment of severe tremor 
in YOPD. The therapeutic approach differs in late and early 
phase of PD. In the late stage of PD in YOPD, motor com-
plications such as wearing-off, unpredictable offs, and dys-
kinesias predominate. Therefore addition and manipulation 
of doses of levodopa, dopamine agonists, MAO-B inhibitors, 
and inhibitors of catechol-O-methyltranferase (COMT) can 
all be helpful in improving these complications. COMT 
inhibitors in combination with levodopa enhance efficacy 
of levodopa on motor symptoms of PD due to prolongation 
of its effect.
Despite all the therapeutic possibilities for treating 
YOPD, one must bear in mind that YOPD patients face a 
lifetime of a progressive disease and many years of therapy. 
When manipulations of oral antiparkinsonian drugs are 
exhausted, patients with YOPD may be good candidates for 
continuous apomorphine infusions, surgery, or continuous 
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levodopa treatment. For years it was believed that levodopa 
may have been toxic to dopaminergic neurons.74,75 Perfor-
mance of levodopa infusions is a rather complex and expen-
sive technique, which was a reason for restricting levodopa 
therapy for many years. Now opinions are changing, and it 
is believed that the decreased response to levodopa in late 
Parkinson’s is due to progression of disease rather than toxic 
effects.76 Moreover, it is thought that continued delivery of 
levodopa to the brain help to prevent and improve motor 
complications. Physiological continuous stimulation of the 
dopaminergic neurons has been explored through duodenal, 
intrajejunal, or subcutaneous infusions. It has been shown 
that continuous stimulations improve motor symptoms.77
Surgery
Deep brain stimulation (DBS)
DBS is an FDA-approved surgical technique whereby 
electrical current is applied to various parts of the brain via 
implanted electrodes.78 In contrast to ablative procedures, it 
proves to be a safer method in the treatment of movement 
disorders, producing adverse effects that are generally revers-
ible once the stimulation is terminated.79 The underlying 
mechanisms of DBS are not completely understood, although 
growing evidence supports the efficacy of DBS for the treat-
ment of movement disorders including PD.79
Over the years, many targets have been used for the treat-
ment of PD, including ventral intermediate nucleus (VIM), 
subthalmic nucleus (STN), and globus pallidus interna 
(GPi).79 Benabid et al found that in a series of 80 PD patients 
treated with either unilateral or bilateral VIM DBS, 88% had 
complete or near-complete tremor relief on the Fahn–Tolosa–
Marin Tremor Rating Scale at 6 months to 8 years postopera-
tively.80 The effects of VIM DBS on other symptoms of PD 
such as rigidity, bradykinesia, or drug-induced dyskinesia 
were either short lasting or nonexistent.80 STN DBS does 
not improve on-medication state UPDRS motor subscores 
but does lead to 52% improvement in the off-medication 
state UPDRS scores over a period of 15 months postopera-
tively.81 A 50%–60% reduction in postoperative levodopa 
dose leads indirectly to improvement in levodopa-induced 
dyskinesia.81,82 On-medication dyskinesias are reduced by 
94% after 12 months of STN DBS.82 Quality of life is sig-
nificantly improved after STN DBS compared with medical 
therapy.78,83 However, recent data suggest that, although 
STN DBS improves motor components in both young and 
old patients, it is less effective in patients older than 65.84 
Nevertheless, a recent study by Odekerken et al suggests that 
STN could be the preferred target for DBS in patients with 
advanced PD.85 DBS-associated problems in cognitive, mood, 
and behavioral features seem to occur more often in the STN 
stimulation.85–89 In PD patients, GPi DBS improves tremor, 
rigidity, and bradykinesia in off-medication state as well as 
drug-induced bradykinesia, resulting in overall improve-
ment in UPDRS motor scores.90–92 The most pronounced 
and long-lasting effect is the reduction in on-medication 
dyskinesia.93 GPi DBS does not lead to reduction in the 
patient’s levodopa requirement and might even increase after 
chronic GPi DBS therapy.94 YOPD patients are usually char-
acterized by a slower disease progression, lower incidence of 
non-levodopa responsive symptoms, and more severe motor 
complications,18,95–97 thus representing ideal candidates for 
the DBS surgical option.98 A study by Merola et al showed 
that STN DBS-treated YOPD patients were associated with 
a medium- to long-term lower incidence of stimulation and 
medication resistant symptoms.98
Ablation
Currently, the options for ablation therapy include pallido-
tomy or thalamotomy, where the target structure may either 
be the globus pallidus or the thalamus. Palidotomy has been 
shown to reduce drug-induced dyskinesias and dystonias in 
PD patients who have previously had a successful response 
to pharmacological therapy.99 A unilateral pallidotomy usu-
ally improves symptoms on the contralateral side.100 There 
is a dispute whether a bilateral pallidotomy is a completely 
safe procedure.101
As with the pallidotomy a unilateral thalamotomy will be 
effective against symptoms on the contralateral side. It may 
improve tremor, rigidity, and dyskinesias but may worsen 
other parkinsonian symptoms such as bradykinesia, gait 
problems, postural instability, or speech disorders.74,102
Currently there is a new noninvasive method which 
is emerging and has been approved by the FDA to enroll 
30 patients in its study for ablation by transcranial magnetic 
resonance (MR) imaging-guided focused ultrasound.102 It uses 
focused ultrasound waves, which converge at a specific point 
determined and guided by MR to ablate the malfunctioning 
structure in the brain (nucleus ventralis intermidius of the 
thalamus). The procedure includes real-time continuous MR 
imaging and MR thermometry monitoring, creating a very 
precise, safe, and effective way to treat patients.100,102–104
Novel therapies
Emerging therapeutic options for treating idiopathic PD, 
such as neurotrophic factors, cell-based therapy, neurotrans-
mitter targets, and potentially neuroprotective drugs, are 
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generating much interest but also controversy.105–108 Most 
recent treatment options for PD involve immunotherapy 
through vaccination and gene therapy. However, most of these 
treatment options focus very little on the YOPD subgroup 
of patients. Further research is needed to test their efficacy 
on YOPD patients specifically. These therapies are currently 
in experimental stages of development and have not been 
FDA approved.
Cell-based therapy
Cell-based therapy for PD has shown significant progress in 
recent years.104 A major advancement came with the use of 
fetal ventral mesencephalic (VM) tissue as a cell source for 
transplantation. Fetal dopamine (DA) neurons transplanted 
into the striatum of PD patients have survived, integrated, and 
provided motor benefits.109–111 The first neural transplantation 
used dissociated fetal VM tissue, which was transplanted into 
the striatum of young PD patients. Marked motor improve-
ment and increased fluorodopa uptake in the striatum on 
positron emission tomography (PET) was observed.109 Indi-
rect evidence of graft survival, obtained from PET studies, 
indicated that the transplanted fetal VM tissue can survive 
up to a decade and provide sustained motor benefits in PD.112 
Additionally, it was shown that DA neuronal suspension 
grafts can survive, integrate, and display mature VM pheno-
types providing functional benefits in the degenerating brain 
for years without side effects such as dyskinesia.113 In a trial 
with solid pieces of fetal VM tissue, clinical improvement 
was, to some degree, observed in YOPD but not in non-YOPD 
patients.111
immunotherapy
PD, as the second most common neurodegenerative entity, is 
of particular interest with regard to applying immunotherapy 
in clinical practice.88 The major component of Lewy bodies, 
and neuropathological hallmark of PD, is α-synuclein.88 The 
first experimental indication that α-synuclein might be the 
causative agent in PD came from the analysis of rare auto-
somal dominant forms of PD in several families carrying 
three different point mutations in the SNCA gene leading to 
the formation of misfolded protein.88 Masliah et al investi-
gated mice overexpressing human SNCA and either admin-
istrated a full-length α-synuclein-based vaccine employing 
CFA/IFA (Freund’s complete/incomplete adjuvant) as 
adjuvant89 or systemically administrated an α-synuclein-
specific monoclonal antibody.114 Both therapies were associ-
ated with reduced neurodegeneration and improved function. 
Recently, AFFITOPE® PD01 vaccine has been developed 
to induce antibodies recognizing α-synuclein.88 Preclinical 
studies involving the subcutaneous administration of the 
vaccine demonstrated reactivity towards α-synuclein with 
an additional functional benefit.88 Compared with controls, 
PD01-treated animals showed superior cognitive functions 
as assessed by the Morris water maze test.88
Gene therapy
In-vivo gene therapy is a new approach.115 Gene transfer of 
glutamic acid decarboxylase (GAD), rate-limiting enzyme 
in gamma-aminobutyric acid (GABA) production, and 
other methods that modulate the production of GABA in 
the subthalmic nucleus, improve basal ganglia function in 
parkinsonism in animal models.115 LeWitt et al assessed the 
effect of bilateral delivery of adeno-associated viral vector 
(AAV2)-GAD in the subthalmic nucleus compared with sham 
surgery in patients with advanced PD. The AVV2-GAD group 
showed significant improvement from baseline in unified PD 
rating scale (UPDRS) scores compared with sham group 
over the course of 6 months.115 A similar study involving 
neurturin, a naturally occurring analogue of glial cell-line-
derived neurotrophic factor, was conducted by Marks et al116 
by bilateral delivery of AAV2-neurturin into the putamen. 
However, it showed no motor score improvement using the 
UPDRS in treated patients after 12 months.116
The selection of the best candidate for surgery among PD 
patients is a debated topic. YOPD patients could be the best 
candidates for this kind of treatment, because they have a 
slower disease progression and more competent compensa-
tory mechanisms, and this could be beneficial for effects of 
transplantations.117
Adjuvant therapies
Physical and occupational therapy in YOPD patients should 
be used with pharmacological treatment and may assist in the 
rehabilitation process. Initiating an exercise program from the 
earliest stages of PD might benefit secondary motor problems 
involving arm swing, gait, and posture.118,119 Exercise has been 
shown to improve physical function, health-related quality of 
life, leg strength, balance, and gait speed in PD, and is pos-
sibly mediated through increased calcium/CaM-dependent 
dopamine synthesis in the remaining dopaminergic nigros-
triatal cells.120,121 Service (trained) dogs are reported to help 
people with PD by interruption of rest tremor on stroking the 
dog and diminishing propulsive gait,118 perhaps by providing 
visual cues.122 YOPD patients with speech difficulties might 
benefit from intensive voice therapy to maintain employment 
and social activity.115
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Conclusion
Many clinicians view age at onset as an important determinant 
of clinical phenotype in PD. YOPD is very similar to LOPD 
in many ways but requires special attention because it is dif-
ferent enough to require a different treatment approach. The 
available evidence suggests that PD patients with younger 
age at onset have slower disease progression, an increased 
rate of dystonia at onset, a lower rate of dementia, and an 
increased rate of dyskinesias in response to levodopa treat-
ment. Which drugs to use when initiating pharmacotherapy 
in YOPD is a complex treatment decision that depends on 
factors such as disease severity, functional disability, and 
psychosocial handicap, as well as individual aspects of 
comorbidity and age. Without clear proof of a drug’s capac-
ity to markedly alter or even stop the progression of the 
disease, there is no strategy that can be viewed as universal 
treatment. Dopamine replacement strategies offer greatest 
symptomatic relief and are needed whenever there is signifi-
cant functional disability. Physicians are slowly gravitating 
towards the notion that levodopa treatment does not have 
toxic effects on dopaminergic neurons; however, preventing 
dyskinesias and motor symptoms which begin shortly after 
levodopa treatment initiation in YOPD patients remains to 
be demonstrated. The therapeutic strategy for YOPD patients 
should include a relatively low threshold for initiation of 
treatment. The treatment should be initiated with a dopamine 
receptor agonist, with the dosage individually adjusted. In 
the cases where the treatment response is suboptimal, or if 
problematic adverse effects develop, levodopa should be 
added to the therapy. YOPD patients are also ideal candidates 
for DBS therapy with medium- to long-term lower incidence 
of stimulation and medication resistant symptoms. Regular 
physical exercise and physical therapy must be encouraged. 
Emerging therapeutic options for the treatment of YOPD, 
such as cell-based therapy are generating much interest from 
the scientific community, although their effectiveness remains 
to be established. Future therapeutic strategies should focus 
not only on ameliorating the symptoms of PD, but also on 
neuroprotective or neurorescue therapies that can favorably 
modify the natural course of the disease and slow the pro-
gression of manifestations of PD. YOPD patients are not only 
bearing the burden of motor complications but psychological 
problems, often overlooked, and a general decrease in the 
quality of life. Many studies have shown that proper treatment 
can significantly increase the quality of life in YOPD patients. 
For this reason, a custom tailored treatment plan is of inter-
est, based on stage of the disease, degree of interference of 
the symptoms with social and occupational functioning, and 
response to treatment. The medical management of YOPD 
is complicated, and a multidisciplinary approach to care is 
vital to meet the psychological, emotional, and social needs 
of PD patients and their families.
Key points
•	 Diagnosis of PD before the age of 40 is considered 
YOPD.
•	 When suspecting YOPD, secondary causes of parkinso-
nian symptoms should be excluded (Wilson’s disease, 
dopa-responsive dystonia, drug-induced parkinsonism, 
and structural abnormalities).
•	 After 6 years of levodopa therapy, almost all YOPD 
patients develop dyskinesias.
•	 Starting therapy with dopamine agonists delays the onset 
of levodopa-related motor symptoms until therapy with 
levodopa is initiated.
•	 DBS and ablation are available surgical options in the 
treatment of YOPD.
•	 Cell-based therapy, immunotherapy, and gene therapy 
are emerging therapeutic options in YOPD treatment.
•	 Physical and occupational therapy in YOPD patients 
should be used as an adjuvant therapy and may assist in 
the rehabilitation process.
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